Table 4 Multivariable model of variables associated with adherence to endocrine therapy among women who were eligible for Oncotype Dx testing (N = 3949)

Tested

.09

 Yes

0.88

(0.76–1.02)

 No (ref)

Year diagnosed

0.003

 2006–2007 (ref)

 2008–2009

0.81

(0.70–0.94)

 2010

0.74

(0.60–0.90)

Age at diagnosis, years

0.047

 24–39

1.50

(1.12–2.01)

 40–49

1.05

(0.88–1.25)

 50–59 (ref)

 60–63

1.00

(0.83–1.20)

Race-ethnicity

0.06

 NH white (ref)

 NH black

1.43

(1.01–2.03)

 Hispanic

1.04

(0.74–1.45)

 Other

0.80

(0.61–1.04)

Marital status

0.003

 Married (ref)

 Not married

1.24

(1.07–1.44)

Prior cancer

0.30

 No (ref)

 Yes

0.85

(0.62–1.16)

State

0.17

 CA (ref)

 GA

1.08

(0.85–1.39)

 KY

0.91

(0.69–1.21)

 NY

0.82

(0.64–1.05)

 OH

0.91

(0.71–1.18)

Area

0.29

 Rural (ref)

 Urban

0.85

(0.62–1.15)

Median household income

0.20

 1 (lowest (ref))

 2

0.98

(0.79–1.22)

 3

1.11

(0.90–1.37)

 4

0.98

(0.78–1.23)

 5 (highest)

0.86

(0.67–1.09)

Stage

0.75

 I (ref)

 II

0.97

(0.79–1.18)

Nodal involvement

0.68

 N0

1.07

(0.80–1.43)

 N1mic

1.11

(0.88–1.40)

 N1 (ref)

HER2 status

0.49

 Negative

1.03

(0.84–1.27)

 Borderline

1.45

(0.79–2.66)

 Unknown (ref)

Hormone receptor status

0.96

 ER and PR both positive (ref)

 Only ER or PR positive

0.99

(0.82–1.21)

Histological grade

0.22

 1–2 (well/moderately differentiated) (ref)

 3 (poorly or not differentiated)

1.11

(0.94–1.31)

One-year comorbidities

0.006

 0 (ref)

 1 or more

1.33

(1.09–1.62)

Surgery type

0.97

 Breast-conserving surgery (ref)

 Mastectomy

1.00

(0.87–1.15)

Endocrine therapy

0.003

 Tamoxifen only (ref)

 AIs only

0.77

(0.64–0.92)

 Tamoxifen and AIs

1.02

(0.85–1.24)

Chemotherapy

0.31

 Yes

0.92

(0.78–1.08)

 No (ref)